<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137809">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01824381</url>
  </required_header>
  <id_info>
    <org_study_id>MA/GH</org_study_id>
    <secondary_id>2011-004395-11</secondary_id>
    <nct_id>NCT01824381</nct_id>
  </id_info>
  <brief_title>Use of the Amniotic Membrane in Large Wound Epithelialization</brief_title>
  <acronym>MA/GH</acronym>
  <official_title>Use of the Amniotic Membrane in Large Wound Epithelialization. Phase I Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Red de Terapia Celular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación para la Formación e Investigación Sanitarias de la Región de Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Facultad de Medicina. Universidad de Murcia.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MurciaSalud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consejería de Sanidad de la Comunidad Autónoma de la Región de Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Red de Terapia Celular</source>
  <oversight_info>
    <authority>Spain: Ministry of Health</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the security application of the amniotic membrane in
      extensive wounds in the granulation phase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Last revision at 3 years after surgery.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>No serious adverse events possibly, probably or definitely related with the procedure.
No appearance of clinical inflammatory changes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of the wound area</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the effects of the application of the amniotic membrane on reepithelialization of wounds by measuring the wound area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of local pain measured with a visual analog scale</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the effects of the application of amniotic membrane in the symptomatology of patients through the development of local pain measured with a visual analog scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the signaling pathways of TGFb.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To study the changes in the signaling pathways of TGFb in patients epithelium induced amniotic membrane.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Wounds</condition>
  <arm_group>
    <arm_group_label>Amniotic membrane in large wounds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Place amniotic membrane in large wounds</intervention_name>
    <description>After the process of obtaining the amniotic membrane, it must be processed, frozen and thawed.
The wound is washed with saline and, if necessary it will be debrided. We will take microbiological control cultures. Then apply the amniotic membrane fragments sufficient to cover the wound by contacting the basal membrane of the amniotic membrane with granulation tissue.
We will place a new membrane weekly to a maximum of 6 times.</description>
    <arm_group_label>Amniotic membrane in large wounds</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Obtaining and Cryopreservation of amniotic membrane</intervention_name>
    <arm_group_label>Amniotic membrane in large wounds</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amniotic membrane</intervention_name>
    <arm_group_label>Amniotic membrane in large wounds</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute wounds in granulation phase with a minimum area of ​​100 cm2.

          -  Patients 18 or more years.

          -  Patients offering sufficient guarantees of adherence to protocol.

          -  Sign the written informed consent.

          -  Meet all inclusion criteria.

        Exclusion Criteria:

          -  Patients with symptomatic chronic arterial insufficiency.

          -  Patients who are pregnant

          -  Patients in active lactation

          -  Patients physically fertile, defined as all women physiologically capable of becoming
             pregnant, including women whose career, lifestyle or sexual orientation precludes
             intercourse with a man and women whose partners have been sterilized by vasectomy or
             other methods, UNLESS they are using reliable contraception. This method of
             contraception can be:

               -  Complete abstinence from sexual intercourse

               -  Surgical sterilization (tubal ligation)

               -  Surgical sterilization of the partner (vasectomy)

               -  Implanted or injectable hormonal contraceptives, oral *

               -  Because hormonal contraceptives have a risk of thrombosis, should consider other
                  methods of birth control.

        These reliable contraception must be maintained during their participation in the study.

          -  Patients with heart, kidney, liver, systemic immune may influence the survival of the
             patient during the test.

          -  Participation in other clinical trials.

          -  Inability to understand informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregorio Castellanos-Escrig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Universitary Hospital Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gregorio Castellanos-Escrig, MD</last_name>
    <phone>+34968369532</phone>
    <email>gcastellanos@ono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Javier Judez-Gutierrez, MD</last_name>
    <phone>+34968359777</phone>
    <email>ffis-investigacion-sms@listas.carm.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Universitary Hospital Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Judez, MD</last_name>
      <phone>+34968359777</phone>
      <email>ffis-investigacion-sms@listas.carm.es</email>
    </contact>
    <investigator>
      <last_name>Gregorio Castellanos Escrig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Piñero Madrona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José M Moraleda Jiménez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Blanquer Blanquer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andres Sanchez Salinas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana M García Hernández, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joaquín A Gómez Espuch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisca Iniesta Martínez, Graduate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco J Nicolás Villaescusa, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique Martínez Barba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Muro Amador, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Genoveva Yagüe Guirao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Santoyo Santonja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.red-tercel.com</url>
    <description>Official web of Spanish Stem Cell Network</description>
  </link>
  <link>
    <url>http://www.ffis.es</url>
    <description>Fundación para la Formación e Investigación Sanitarias Región de Murcia</description>
  </link>
  <link>
    <url>http://www.murciasalud.es</url>
    <description>Official web of Health Service of Murcia Region.</description>
  </link>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>April 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>extensive wounds</keyword>
  <keyword>amniotic membrane</keyword>
  <keyword>healing</keyword>
  <keyword>patients</keyword>
  <keyword>phase granulation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
